The stock price of Travere Therapeutics Inc (NASDAQ: TVTX) has surged by 3.22 when compared to previous closing price of 17.86, but the company has seen a -0.19% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-18 that NEW YORK, Nov. 18, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Is It Worth Investing in Travere Therapeutics Inc (NASDAQ: TVTX) Right Now?
The 36-month beta value for TVTX is also noteworthy at 0.68. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 6 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TVTX is 85.72M, and at present, short sellers hold a 9.32% of that float. The average trading volume of TVTX on November 21, 2024 was 1.89M shares.
TVTX’s Market Performance
The stock of Travere Therapeutics Inc (TVTX) has seen a -0.19% decrease in the past week, with a 2.64% rise in the past month, and a 105.29% gain in the past quarter. The volatility ratio for the week is 4.98%, and the volatility levels for the past 30 days are at 6.15% for TVTX. The simple moving average for the past 20 days is 2.17% for TVTX’s stock, with a 81.43% simple moving average for the past 200 days.
Analysts’ Opinion of TVTX
Many brokerage firms have already submitted their reports for TVTX stocks, with Wells Fargo repeating the rating for TVTX by listing it as a “Overweight.” The predicted price for TVTX in the upcoming period, according to Wells Fargo is $27 based on the research report published on October 21, 2024 of the current year 2024.
Guggenheim gave a rating of “Buy” to TVTX, setting the target price at $25 in the report published on September 09th of the current year.
TVTX Trading at 10.52% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.32% of loss for the given period.
Volatility was left at 6.15%, however, over the last 30 days, the volatility rate increased by 4.98%, as shares surge +1.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +45.32% upper at present.
During the last 5 trading sessions, TVTX fell by -0.87%, which changed the moving average for the period of 200-days by +121.14% in comparison to the 20-day moving average, which settled at $18.04. In addition, Travere Therapeutics Inc saw 105.06% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVTX starting from LYONS GARY A, who sale 40,000 shares at the price of $14.73 back on Oct 04 ’24. After this action, LYONS GARY A now owns 51,000 shares of Travere Therapeutics Inc, valued at $589,101 using the latest closing price.
GARY A LYONS, the Officer of Travere Therapeutics Inc, proposed sale 40,000 shares at $13.65 during a trade that took place back on Oct 04 ’24, which means that GARY A LYONS is holding shares at $546,000 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -1.69 for the present operating margin
- 0.84 for the gross margin
The net margin for Travere Therapeutics Inc stands at -1.73. The total capital return value is set at -1.09. Equity return is now at value -279.94, with -52.19 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 1.09 points at debt to capital in total, while cash flow to debt ratio is standing at -0.71. The debt to equity ratio resting at -12.6. The interest coverage ratio of the stock is -30.74.
Currently, EBITDA for the company is -326.25 million with net debt to EBITDA at -1.24. When we switch over and look at the enterprise to sales, we see a ratio of 9.59. The receivables turnover for the company is 8.08for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.71.
Conclusion
In summary, Travere Therapeutics Inc (TVTX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
